about
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.Plasmodium vivax Controlled Human Malaria Infection - Progress and ProspectsA pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugsSafety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.MALDI-TOF MS meets WGS in a VRE outbreak investigation.Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria TransmissionPiperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite.A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers.An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.Delusions of disseminated fungosis.The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study.Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects.Fasting increases serum bilirubin levels in clinically normal, healthy males but not females: a retrospective study from phase I clinical trial participants.
P50
Q27324132-7B9DF9F0-0CF3-4398-A179-95CBF48C8324Q28066456-91FD2187-4A76-4854-B853-9F36DA578DF1Q28476638-6878947C-11AF-44EE-A738-130ACCA46A9EQ33732740-C61BAE9B-8563-45EA-A8B2-22D3959C362FQ35595618-FC75BC03-06E0-434B-837C-22970AF7DD4DQ36204758-605C00FA-B1A7-4E6F-AC4A-FD1E1E00A529Q36215894-76CF9267-20AF-4C55-9BD6-20C9B0F04425Q37003081-01F1E6C0-A9BA-44C0-9F20-4B1D5EF4DD12Q37193141-CBF5AC42-D312-4F9A-919C-10B9D11AC70EQ37199873-6C213CEF-58CB-437F-9437-B409D9F1C5F1Q37254756-ED90ED6C-5D68-42AE-AA74-67ECE3A58309Q37463375-540FA35E-52CB-4515-A253-B44C0C56AB38Q37561211-E5613362-200A-4AE2-8DE8-B69DF9EB2A79Q38327964-41C41A58-DC76-4ADE-8089-FADBFD1D1CE4Q50048765-4BB7264C-FD68-4515-8642-4254E34FC6CDQ50091418-7CA0C93F-2927-4779-A660-979BAD70CC5CQ51326168-2FDC04C1-E646-4ABB-855A-3EA34F0F43B9
P50
description
researcher
@en
հետազոտող
@hy
name
Paul Griffin
@ast
Paul Griffin
@en
Paul Griffin
@es
Paul Griffin
@nl
type
label
Paul Griffin
@ast
Paul Griffin
@en
Paul Griffin
@es
Paul Griffin
@nl
prefLabel
Paul Griffin
@ast
Paul Griffin
@en
Paul Griffin
@es
Paul Griffin
@nl
P108
P106
P31
P496
0000-0002-1656-421X